Titan Biotech's Q4 FY 2025-26 Quarterly Results

Result Summary

• Titan Biotech Ltd reported a 11.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 39.4%.
• Its expenses for the quarter were down by 13.9% QoQ and up 29.0% YoY.
• The net profit decreased 21.1% QoQ and increased 66.2% YoY.
• The earnings per share (EPS) of Titan Biotech Ltd stood at 1.63 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Titan Biotech Ltd is a company engaged in the biotech industry, known for producing and supplying a range of products such as peptones, protein hydrolysates, and other culture media used in the pharmaceutical, food, and agriculture sectors. The company is well-established in the biotechnology space, providing essential raw materials for microbiological, biotechnological, and chemical laboratories. Information on any recent major developments specific to Titan Biotech Ltd is not available within the provided data.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), Titan Biotech Ltd reported a total income of ₹50.94 crores. This reflects a quarter-over-quarter (QoQ) decrease of 11.8% from the previous quarter (Q3FY26), where the total income stood at ₹57.76 crores. However, when comparing year-over-year (YoY) figures, there was a significant increase of 39.4% from ₹36.55 crores in Q4FY25. This indicates a substantial gain in revenue over the year, despite the dip in the most recent quarter.

Profitability

For Q4FY26, the profit before tax for Titan Biotech Ltd was ₹10.28 crores, showing a slight decline of 2.7% QoQ from ₹10.56 crores in Q3FY26. On a YoY basis, there was a remarkable increase of 104.4% compared to ₹5.03 crores in Q4FY25. The tax expense for the quarter was ₹3.73 crores, which is a 38.7% increase QoQ from ₹2.69 crores and a 196.0% increase YoY from ₹1.26 crores. Profit after tax for Q4FY26 was ₹6.73 crores, which represents a 21.1% decrease QoQ from ₹8.53 crores but a 66.2% increase YoY from ₹4.05 crores. The earnings per share (EPS) for Q4FY26 was ₹1.63, significantly lower than the ₹10.32 reported in Q3FY26 and a decrease from ₹4.90 in Q4FY25.

Operating Metrics

Total expenses for Titan Biotech Ltd in Q4FY26 amounted to ₹40.66 crores, indicating a decrease of 13.9% QoQ from ₹47.21 crores in Q3FY26. Comparatively, this reflects a YoY increase of 29.0% from ₹31.52 crores in Q4FY25. The decrease in expenses during the quarter in contrast to the previous one, coupled with the overall yearly increase, showcases a dynamic cost structure. Financial ratios such as the price-to-earnings (P/E) ratio, debt-to-equity ratio, and current ratio are not calculable with the provided data, as they require additional information such as market price of shares, total debt, and current assets and liabilities.